Lupin Enters Exclusive License Deal with Visus for YUVEZZI in Europe, Up to €75 Mn

Limited has entered into an exclusive license agreement with Visus Therapeutics (part of Tenpoint Therapeutics) for YUVEZZI™, a proprietary ophthalmic product for treating presbyopia in adults, covering Europe, the UK, Switzerland and other licensed territories. Under the agreement, Lupin’s arm VISUfarma will make a strategic investment in Visus. Tenpoint and Visus will be eligible for regulatory and commercial milestone payments as well as tiered royalties, with total potential consideration of up to €75 million. **Top stocks in the pharmaceuticals industry:** Sun Pharmaceutical Industries, Cipla, and Dr. Reddy’s Laboratories.